About Reviews AOD-9604: an independent AOD-9604 research literature digest

What this site is

Reviews AOD-9604 is an independent editorial project that publishes summaries of the peer-reviewed research literature on AOD-9604 (hGH fragment 176-191). The site's name — 'reviews' — is an editorial function: it means this site reviews the published record, reading each study in its methodological context and presenting the findings with the same fidelity the research warrants. The literature is thin. The site says so. The Phase IIb endpoint failed. The site says so. The safety record is clean. The site says so.

This site catalogs all fifteen primary citations in the AOD-9604 literature base, organized by research context: preclinical mechanism studies (1983–2001), clinical trial record (2013–2014), osteoarthritis research (2015, 2025), and tangential non-metabolic investigations (2022). Nothing is inflated. Nothing is omitted.

The 'reviews' in the domain name does not connote product reviews, user testimonials, or vendor assessments. It is an editorial modifier — a position the publisher occupies relative to the literature, not a claim about the site's commercial relationship to any product.

What this site is not

Reviews AOD-9604 is not a clinic. We do not employ clinicians and we do not provide medical advice of any kind. We do not manufacture, sell, or distribute any product. We have no commercial relationship to AOD-9604, to Metabolic Pharmaceuticals Ltd, or to any supplier of research chemicals.

We do not recommend dosing protocols. Every dosage figure on this site is attributed to a specific published protocol in a specific trial or study — it describes what researchers administered to which species under which conditions, not what any person should do.

We do not provide a list of vendors, a pricing guide, or a sourcing recommendation. The site does not contain affiliate links and does not earn revenue from any product transaction.

The 'doctor' modifier is absent from this domain name; 'reviews' is the modifier, and it is editorial. The regulatory context of AOD-9604 is stated plainly on every relevant page: not approved as a pharmaceutical drug, FDA GRAS as a nutraceutical, WADA S0 prohibited in competitive sport, pharmaceutical development discontinued 2007.

The editorial standard

Every quantitative claim on this site is cited to a numbered reference in the citations list. Claims that are not supported by identified published literature are either absent or explicitly marked as 'not identified in the literature reviewed.' The site does not invent citations. It does not extrapolate beyond what the studies measured.

The AOD-9604 research record is reviewed honestly: the strong animal-model evidence is presented as strong animal-model evidence; the Phase IIa signal is presented as a Phase IIa signal; the Phase IIb failure is presented as a Phase IIb failure; the safety record is presented as an exceptional safety record. All four of these things are true simultaneously, and this site presents all four.

For half-life and pharmacokinetics data, the site notes where specific values are absent from the published literature rather than citing general peptide pharmacokinetics as AOD-9604-specific data.